Rhi Haewon, Choi Hyo Geun, Kang Jeong Wook
Department of Otorhinolaryngology-Head & Neck Surgery, Hallym University Sacred Heart Hospital, Anyang, 14068, Republic of Korea.
Suseo Seoul ENT Clinic and MD Analytics, 10, Bamgogae-ro 1-gil, Gangnam-gu, Seoul, 06349, Republic of Korea.
Eur Arch Otorhinolaryngol. 2025 Mar;282(3):1443-1457. doi: 10.1007/s00405-024-09020-1. Epub 2024 Oct 23.
Dyslipidemia and statin use are associated with an increased risk of various cancers. However, the association in head and neck cancer (HNC) remains unclear. Therefore, this study aimed to investigate the impact of dyslipidemia and statin use on the development of HNC.
Using data from the Korean National Health Insurance Service-National Sample Cohort from 2002 to 2019, we compared two groups HNC patients (n = 1006) and matched control participants (n = 4024) after propensity score overlap weighted balancing. The odds ratios (ORs) for HNC development according to dyslipidemia and statin use duration were assessed using propensity score overlap-weighted multivariable logistic regression.
Individuals with untreated dyslipidemia had significantly lower odds of developing HNC than those of normal participants (OR 0.70, 95% confidence interval [CI] 0.59-0.82). Conversely, patients with dyslipidemia who received statin therapy (< 60 days) showed a nearly two-fold increase in the odds of HNC (OR 1.94, 95% CI 1.29-2.90). Long-term statin use (≥ 60 days) aligned the odds with those of normal participants (OR 0.89, 95% CI 0.76-1.04).
The adverse effect of short-term statin use on HNC development requires further study, and long-term statin use for dyslipidemia treatment does not increase the odds of HNC.
血脂异常和他汀类药物的使用与多种癌症风险增加相关。然而，其与头颈癌（HNC）之间的关联仍不明确。因此，本研究旨在探讨血脂异常和他汀类药物的使用对HNC发生发展的影响。
利用2002年至2019年韩国国民健康保险服务全国样本队列的数据，在倾向得分重叠加权平衡后，我们比较了两组HNC患者（n = 1006）和匹配的对照参与者（n = 4024）。根据血脂异常和他汀类药物使用时长评估HNC发生的比值比（OR），采用倾向得分重叠加权多变量逻辑回归分析。
未经治疗的血脂异常个体发生HNC的几率显著低于正常参与者（OR 0.70，95%置信区间[CI] 0.59 - 0.82）。相反，接受他汀类药物治疗（< 60天）的血脂异常患者发生HNC的几率增加近两倍（OR 1.94，95% CI 1.29 - 2.90）。长期使用他汀类药物（≥ 60天）使几率与正常参与者相当（OR 0.89，95% CI 0.76 - 1.04）。
短期使用他汀类药物对HNC发生发展的不良影响需要进一步研究，且长期使用他汀类药物治疗血脂异常不会增加HNC发生几率。
